Stem cell particles tested as lifeline for failing livers

NCT ID NCT07409259

Summary

This early-stage study is testing whether injections of tiny particles called exosomes, derived from stem cells, can help control acute-on-chronic liver failure when added to standard care. The trial will enroll 20 patients with this serious liver condition to compare survival rates and symptom improvement between those receiving the exosome treatment plus standard care versus standard care alone. Researchers will closely monitor safety and whether the treatment helps patients live longer and feel better over 12 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Third Affiliated Hospital, Sun Yat-sen University Guangzhou, Guangdong, China 510630

    Guangzhou, Guangdong, 510630, China

Conditions

Explore the condition pages connected to this study.